2-Methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts

Reproductive Sciences

Volumn 15, Issue 9, 2008, Pages 878-894

  Kato, Sumie ^a   Sadarangani, Anil ^a   Lange, Soledad ^b   Delpiano, Ana M ^a   Vargas, MacArena ^a   Brañes, Jorge ^a   Carvajal, Jorge ^a   Lipkowitz, Stanley ^a   Owen, Gareth I ^a   Cuello, Mauricio A ^a,c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NONE   (Chile)

Author keywords

2ME; AIF; Chemotherapy; Death receptors; Ovarian cancer; TRAIL

Indexed keywords

2 METHOXYESTRADIOL; CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; DRUG SYNERGISM; ESTRADIOL; FEMALE; HUMANS; OVARIAN NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 57649097524     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719108324171     Document Type: Article

References (53)

1. Bhoola S., Hoskins WJ Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol. 2006 ; 107: 1399-1410.
2. Parkin DM, Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 ; 55: 74-108.
3. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A., Hartmann LC Current management strategies for ovarian cancer. Mayo Clin Proc. 2007 ; 82: 751-770.
4. Lage H., Denkert C. Resistance to chemotherapy in ovarian carcinoma. Recent Results Cancer Res. 2007 ; 176: 51-60.
5. Beral V., Bull D., Green J., Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007 ; 369: 1703-1710.
6. Glud E., Kjaer SK, Thomsen BL, et al. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med. 2004 ; 164: 2253-2259.
7. Whittemore AS, Harris R., Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol. 15 1992 ; 136: 1212-1220.
8. Ho SM Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol. 2003 ; 1: 73.
9. Syed V., Mukherjee K., Godoy-Tundidor S., Ho SM Progesterone induces Apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIP(L) overexpression. J Cell Biochem. 2007 ; 102: 442-52.
10. Syed V., Ulinski G., Mok SC, Ho SM Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst. 2002 ; 94: 617-629.
11. Utsumi T., Leese MP, Chander SK, et al. The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells. J Steroid Biochem Mol Biol. 2005 ; 94: 219-227.
12. Ricker JL, Chen Z., Yang XP, Pribluda VS, Swartz GM, Van Waes C. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res. 2004 ; 10: 8665-8673.
13. Kimbro KS, Simons JW Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer. 2006 ; 13: 739-749.
14. Merriam GR, MacLusky NJ, Picard MK, Naftolin F. Comparative properties of the catechol estrogens, I: methylation by catechol-O-methyltransferase and binding to cytosol estrogen receptors. Steroids. 1980 ; 36: 1-11.
15. Van Aswegen CH, Purdy RH, Wittliff JL Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers. J Steroid Biochem. 1989 ; 32: 485-492.
16. Sidor C., D'Amato R., Miller KD The potential and suitability of 2-methoxyestradiol in cancer therapy. Clin Cancer Res. 2005 ; 11: 6094-6095 ; author reply 6095-6096.
17. Qadan LR, Perez-Stable CM, Anderson C., et al. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun. 2001 ; 285: 1259-1266.
18. Van Veldhuizen PJ, Ray G., Banerjee S., et al. 2-Methoxyestradiol modulates beta-catenin in prostate cancer cells: a possible mediator of 2-methoxyestradiol-induced inhibition of cell growth. Int J Cancer. 2008 ; 122: 567-571.
19. Casarez EV, Dunlap-Brown ME, Conaway MR, Amorino GP Radiosensitization and modulation of p44/42 mitogen-activated protein kinase by 2-Methoxyestradiol in prostate cancer models. Cancer Res. 2007 ; 67: 8316-8324.
20. Lin HL, Yang MH, Wu CW, et al. 2-Methoxyestradiol attenuates phosphatidylinositol 3-kinase/Akt pathway-mediated metastasis of gastric cancer. Int J Cancer. 2007 ; 121: 2547-2555.
21. Thews O., Lambert C., Kelleher DK, Biesalski HK, Vaupel P., Frank J. Possible protective effects of alpha-tocopherol on enhanced induction of reactive oxygen species by 2-methoxyestradiol in tumors. Adv Exp Med Biol. 2005 ; 566: 349-355.
22. Joubert A., Maritz C., Joubert F. Bax/Bcl-2 expression levels of 2-methoxyestradiol-exposed esophageal cancer cells. Biomed Res. 2005 ; 26: 131-134.
23. Zhou NN, Zhu XF, Zhou JM, et al. 2-Methoxyestradiol induces cell cycle arrest and apoptosis of nasopharyngeal carcinoma cells. Acta Pharmacol Sin. 2004 ; 25: 1515-1520.
24. LaVallee TM, Zhan XH, Johnson MS, et al. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res. 2003 ; 63: 468-475.
25. Bu S., Blaukat A., Fu X., Heldin NE, Landstrom M. Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett. 2002 ; 531: 141-151.
26. Gibson SB Epidermal growth factor and trail interactions in epithelial-derived cells. Vitam Horm. 2004 ; 67: 207-227.
27. Kurbanov BM, Geilen CC, Fecker LF, Orfanos CE, Eberle J. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol. 2005 ; 125: 1010-1019.
28. Ray S., Bucur O., Almasan A. Sensitization of prostate carcinoma cells to Ap02L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis. 2005 ; 10: 1411-1418.
29. Shi J., Zheng D., Liu Y., et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res. 2005 ; 65: 1687-1692.
30. Meurette O., Fontaine A., Rebillard A., et al. Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells. Ann N Y Acad Sci. 2006 ; 1090: 209-216.
31. Sadarangani A., Kato S., Espinoza N., et al. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis. 2007 ; 12: 73-85.
32. Shi J., Zheng D., Man K., Fan ST, Xu R. TRAIL: a potential agent for cancer therapy. Curr Mol Med. 2003 ; 3: 727-736.
33. Cuello M., Coats AO, Darko I., et al. N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ. 2004 ; 11: 527-541.
34. Cuello M., Ettenberg SA, Nau MM, Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol. 2001 ; 81: 380-390.
35. Kato S., Sadarangani A., Lange S., et al. The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium. Endocr Relat Cancer. 2007 ; 14: 351-368.
36. Lane D., Cartier A., L'Esperance S., Cote M., Rancourt C., Piche A. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Gynecol Oncol. 2004 ; 93: 594-604.
37. Tomek S., Horak P., Pribill I., et al. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol Oncol. 2004 ; 94: 107-114.
38. Catley L., Tai YT, Chauhan D., Anderson KC Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist Updat. 2005 ; 8: 205-218.
39. Leverkus M., Neumann M., Mengling T., et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 2000 ; 60: 553-559.
40. Vignati S., Codegoni A., Polato F., Broggini M. Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur J Cancer. 2002 ; 38: 177-183.
41. Cuello M., Ettenberg SA, Clark AS, et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001 ; 61: 4892-4900.
42. Beale PJ, Rogers P., Boxall F., Sharp SY, Kelland LR BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer. 2000 ; 82: 436-440.
43. Gibson EM, Henson ES, Haney N., Villanueva J., Gibson SB Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer Res. 2002 ; 62: 488-496.
44. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 ; 162: 156-159.
45. Tsao SW, Mok SC, Fey EG, et al. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res. 1995 ; 218: 499-507.
46. Yager JD Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr. 2000 ;(27). 67-73.
47. Yager JD, Liehr JG Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol. 1996 ; 36: 203-232.
48. Watanabe K., Takanashi K., Imaoka S., et al. Comparison of cytochrome P-450 species which catalyze the hydroxylations of the aromatic ring of estradiol and estradiol 17-sulfate. J Steroid Biochem Mol Biol. 1991 ; 38: 737-743.
49. Li L., Bu S., Backstrom T., Landstrom M., Ulmsten U., Fu X. Induction of apoptosis and G2/M arrest by 2-methoxyestradiol in human cervical cancer HeLaS3 cells. Anticancer Res. 2004 ; 24: 873-880.
50. Song JJ, An JY, Kwon YT, Lee YJ Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL. J Biol Chem. 2007 ; 282: 319-328.
51. Kondo K., Yamasaki S., Inoue N., et al. Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma. Surg Today. 2006 ; 36: 966-974.
52. Singh TR, Shankar S., Chen X., Asim M., Srivastava RK Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 2003 ; 63: 5390-5400.
53. Basu A., Castle VP, Bouziane M., Bhalla K., Haldar S. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Res. 2006 ; 66: 4309-4318.